Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

If we build it they will come: targeting the immune response to breast cancer.

Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky K, Abdul Sater H, Sparano JA, Cescon D, Page DB, McArthur H, Adams S, Mittendorf EA.

NPJ Breast Cancer. 2019 Oct 29;5:37. doi: 10.1038/s41523-019-0133-7. eCollection 2019. Review.

2.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.

Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S.

NPJ Breast Cancer. 2019 Oct 8;5:34. doi: 10.1038/s41523-019-0130-x. eCollection 2019. Review.

3.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr.

JAMA Oncol. 2019 Sep 30. doi: 10.1001/jamaoncol.2019.4794. [Epub ahead of print]

PMID:
31566680
4.

Clinical and Genomic Risk in Adjuvant Therapy for Breast Cancer. Reply.

Sparano JA.

N Engl J Med. 2019 Sep 26;381(13):1290-1291. doi: 10.1056/NEJMc1909693. No abstract available.

PMID:
31553846
5.

TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps.

Sparano JA, Gray R.

J Clin Oncol. 2019 Jul 20;37(21):1841-1842. doi: 10.1200/JCO.19.00828. Epub 2019 Jun 7. No abstract available.

PMID:
31173552
6.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.

7.

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.

Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D.

J Clin Oncol. 2019 Sep 1;37(25):2206-2216. doi: 10.1200/JCO.19.00882. Epub 2019 Jun 3.

8.

Applying the Hippocratic Oath in breast cancer-The case for promoting prevention.

Anampa JD, McEvoy MP, Feldman S, Sparano JA.

Breast J. 2019 Mar;25(2):187-189. doi: 10.1111/tbj.13152. No abstract available.

PMID:
30834671
9.

Techniques and Thresholds for Quantifying Circulating Tumor Cells in Breast Cancer-In Reply.

Sparano JA.

JAMA Oncol. 2019 Apr 1;5(4):574. doi: 10.1001/jamaoncol.2018.7236. No abstract available.

PMID:
30789630
10.

Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment.

Lehman CD, Gatsonis C, Romanoff J, Khan SA, Carlos R, Solin LJ, Badve S, McCaskill-Stevens W, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Gareen I, Snyder BS, Wagner LI, Miller KD, Sparano JA, Comstock C.

JAMA Oncol. 2019 Jul 1;5(7):1036-1042. doi: 10.1001/jamaoncol.2018.6269.

11.

Gene Expression Assays in Early-Stage Breast Cancer.

Sparano JA.

Oncology (Williston Park). 2018 Oct 15;32(10):510-2. No abstract available.

12.

Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?

Sparano JA, Henry NL.

J Natl Cancer Inst. 2019 Apr 1;111(4):339-341. doi: 10.1093/jnci/djy153. No abstract available.

13.

Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.

Jayasekera J, Schechter CB, Sparano JA, Jagsi R, White J, Chapman JW, Whelan T, Anderson SJ, Fyles AW, Sauerbrei W, Zellars RC, Li Y, Song J, Huang X, Julian TB, Luta G, Berry DA, Feuer EJ, Mandelblatt J; CISNET-BOLD Collaborative Group.

J Natl Cancer Inst. 2018 Dec 1;110(12):1370-1379. doi: 10.1093/jnci/djy128.

14.

Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer.

Pastoriza JM, Karagiannis GS, Lin J, Lanjewar S, Entenberg D, Condeelis JS, Sparano JA, Xue X, Rohan TE, Oktay MH.

Clin Exp Metastasis. 2018 Oct;35(7):613-623. doi: 10.1007/s10585-018-9932-8. Epub 2018 Aug 22.

15.

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).

Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr.

J Clin Oncol. 2018 Sep 1;36(25):2621-2629. doi: 10.1200/JCO.2018.79.2028. Epub 2018 Jul 24.

16.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

17.

Prognostic gene expression assays in breast cancer: are two better than one?

Sparano JA.

NPJ Breast Cancer. 2018 May 22;4:11. doi: 10.1038/s41523-018-0063-9. eCollection 2018. No abstract available.

18.

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.

Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, Hershman DL.

Clin Transl Oncol. 2018 Nov;20(11):1474-1483. doi: 10.1007/s12094-018-1888-2. Epub 2018 May 7.

19.

Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.

Jayasekera J, Li Y, Schechter CB, Jagsi R, Song J, White J, Luta G, Chapman JW, Feuer EJ, Zellars RC, Stout N, Julian TB, Whelan T, Huang X, Shelley Hwang E, Hopkins JO, Sparano JA, Anderson SJ, Fyles AW, Gray R, Sauerbrei W, Mandelblatt J, Berry DA; CISNET-BOLD Collaborative Group.

J Natl Cancer Inst. 2018 Dec 1;110(12):1360-1369. doi: 10.1093/jnci/djy059.

20.

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA.

J Clin Oncol. 2018 Jun 1;36(16):1556-1563. doi: 10.1200/JCO.2017.76.9331. Epub 2018 Apr 17.

PMID:
29664714
21.

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).

Ramos JC, Sparano JA, Rudek MA, Moore PC, Cesarman E, Reid EG, Henry D, Ratner L, Aboulafia D, Lee JY, Ambinder RF, Mitsuyasu R, Noy A.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):180-190.e2. doi: 10.1016/j.clml.2018.01.004. Epub 2018 Feb 2.

22.

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.

Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Davidson NE, Paszat L, Shak S, Sparano JA, Solin LJ.

Breast Cancer Res Treat. 2018 Jun;169(2):359-369. doi: 10.1007/s10549-018-4693-2. Epub 2018 Jan 31.

23.

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.

Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, Sparano JA, Connolly RM.

NPJ Breast Cancer. 2018 Jan 11;4:1. doi: 10.1038/s41523-017-0053-3. eCollection 2018. Review.

24.

Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103.

Schneider BP, Shen F, Jiang G, O'Neill A, Radovich M, Li L, Gardner L, Lai D, Foroud T, Sparano JA, Sledge GW Jr, Miller KD.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00059. Epub 2017 Aug 21.

25.

Neoadjuvant Systemic Therapy for Breast Cancer: Searching for More Effectively Curative Therapies.

Sparano JA.

JAMA Oncol. 2018 Mar 1;4(3):293-295. doi: 10.1001/jamaoncol.2017.4651. No abstract available.

PMID:
29327056
26.

The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance.

Suarez CD, Wu J, Badve SS, Sparano JA, Kaliney W, Littlepage LE.

Oncotarget. 2017 Jul 17;8(65):108534-108547. doi: 10.18632/oncotarget.19308. eCollection 2017 Dec 12.

27.

Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer.

Anampa J, Haque T, Murakhovskaya I, Wang Y, Bachiashvili K, Papazoglu C, Pradhan K, Steidl UG, Sparano JA, Verma A.

Haematologica. 2018 Mar;103(3):e98-e102. doi: 10.3324/haematol.2017.181941. Epub 2017 Nov 30. No abstract available.

28.

New agents for the management of resistant metastatic breast cancer.

Anampa J, Sparano JA.

Expert Opin Pharmacother. 2017 Dec;18(17):1815-1831. doi: 10.1080/14656566.2017.1409206. Epub 2017 Nov 27. Review.

PMID:
29171761
29.

Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034.

Tan CRC, Barta SK, Lee J, Rudek MA, Sparano JA, Noy A.

Leuk Lymphoma. 2018 Aug;59(8):1851-1860. doi: 10.1080/10428194.2017.1403597. Epub 2017 Nov 21.

30.

A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer.

Sparano JA, Gray R, Oktay MH, Entenberg D, Rohan T, Xue X, Donovan M, Peterson M, Shuber A, Hamilton DA, D'Alfonso T, Goldstein LJ, Gertler F, Davidson NE, Condeelis J, Jones J.

NPJ Breast Cancer. 2017 Nov 8;3:42. doi: 10.1038/s41523-017-0043-5. eCollection 2017.

31.

Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.

Anampa J, Chen A, Wright J, Patel M, Pellegrino C, Fehn K, Sparano JA, Andreopoulou E.

Clin Breast Cancer. 2018 Feb;18(1):e135-e142. doi: 10.1016/j.clbc.2017.08.013. Epub 2017 Sep 1.

PMID:
28935542
32.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

33.

Learning from big data: are we undertreating older women with high-risk breast cancer?

Sparano JA, Muss H.

NPJ Breast Cancer. 2016 Jun 8;2:16019. doi: 10.1038/npjbcancer.2016.19. eCollection 2016. No abstract available.

34.

Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.

Karagiannis GS, Pastoriza JM, Wang Y, Harney AS, Entenberg D, Pignatelli J, Sharma VP, Xue EA, Cheng E, D'Alfonso TM, Jones JG, Anampa J, Rohan TE, Sparano JA, Condeelis JS, Oktay MH.

Sci Transl Med. 2017 Jul 5;9(397). pii: eaan0026. doi: 10.1126/scitranslmed.aan0026. Erratum in: Sci Transl Med. 2017 Jul 19;9(399):.

35.

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).

Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW.

Breast Cancer Res Treat. 2017 Sep;165(2):375-382. doi: 10.1007/s10549-017-4310-9. Epub 2017 Jun 16.

36.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.

Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.

37.

Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

Garg MK, Zhao F, Sparano JA, Palefsky J, Whittington R, Mitchell EP, Mulcahy MF, Armstrong KI, Nabbout NH, Kalnicki S, El-Rayes BF, Onitilo AA, Moriarty DJ, Fitzgerald TJ, Benson AB 3rd.

J Clin Oncol. 2017 Mar;35(7):718-726. doi: 10.1200/JCO.2016.69.1667. Epub 2017 Jan 9.

38.

Risk of Recurrence and Mortality in a Multi-Ethnic Breast Cancer Population.

Kabat GC, Ginsberg M, Sparano JA, Rohan TE.

J Racial Ethn Health Disparities. 2017 Dec;4(6):1181-1188. doi: 10.1007/s40615-016-0324-y. Epub 2016 Dec 21.

PMID:
28004356
39.

Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.

Schneider BP, Shen F, Gardner L, Radovich M, Li L, Miller KD, Jiang G, Lai D, O'Neill A, Sparano JA, Davidson NE, Cameron D, Gradus-Pizlo I, Mastouri RA, Suter TM, Foroud T, Sledge GW Jr.

Clin Cancer Res. 2017 Jan 1;23(1):43-51. doi: 10.1158/1078-0432.CCR-16-0908. Epub 2016 Dec 19.

40.

Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial.

Sparano JA, Lee JY, Palefsky J, Henry DH, Wachsman W, Rajdev L, Aboulafia D, Ratner L, Fitzgerald TJ, Kachnic L, Mitsuyasu R.

J Clin Oncol. 2017 Mar;35(7):727-733. doi: 10.1200/JCO.2016.69.1642. Epub 2016 Dec 12.

41.

Tailoring Adjuvant Therapy for Breast Cancer in the Elderly: Room for Improvement.

Anampa J, Sparano JA.

Breast J. 2017 May;23(3):253-255. doi: 10.1111/tbj.12730. Epub 2016 Nov 30. No abstract available.

PMID:
27900798
42.

Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.

Schneider BP, Lai D, Shen F, Jiang G, Radovich M, Li L, Gardner L, Miller KD, O'Neill A, Sparano JA, Xue G, Foroud T, Sledge GW Jr.

Oncotarget. 2016 Dec 13;7(50):82244-82253. doi: 10.18632/oncotarget.12545.

43.

Central nervous system involvement in AIDS-related lymphomas.

Barta SK, Joshi J, Mounier N, Xue X, Wang D, Ribera JM, Navarro JT, Hoffmann C, Dunleavy K, Little RF, Wilson WH, Spina M, Galicier L, Noy A, Sparano JA.

Br J Haematol. 2016 Jun;173(6):857-66. doi: 10.1111/bjh.13998. Epub 2016 Apr 7.

44.

A 21-Gene Expression Assay in Breast Cancer.

Sparano JA.

N Engl J Med. 2016 Apr 7;374(14):1387. doi: 10.1056/NEJMc1515988. No abstract available.

PMID:
27050216
45.

In Regard to Bruner et al.

Ohri N, Kalnicki S, Sparano JA, Garg M.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1220-1. doi: 10.1016/j.ijrobp.2015.12.365. Epub 2016 Mar 17. No abstract available.

PMID:
27026322
46.

Reply to C. Shah et al.

Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE.

J Clin Oncol. 2016 May 20;34(15):1824-5. doi: 10.1200/JCO.2016.66.4714. Epub 2016 Mar 21. No abstract available.

PMID:
27001578
47.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

48.

Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).

Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS.

Oncoimmunology. 2015 Jul 27;4(9):e985930. eCollection 2015 Sep.

49.

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families.

Janakiram M, Chinai JM, Zhao A, Sparano JA, Zang X.

Oncoimmunology. 2015 Apr 14;4(8):e1026534. eCollection 2015 Aug.

50.

Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Epeldegui M, Lee JY, Martínez AC, Widney DP, Magpantay LI, Regidor D, Mitsuyasu R, Sparano JA, Ambinder RF, Martínez-Maza O.

Clin Cancer Res. 2016 Jan 15;22(2):328-36. doi: 10.1158/1078-0432.CCR-14-0466. Epub 2015 Sep 17.

Supplemental Content

Loading ...
Support Center